() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: PPP001

Tetra Bio-Pharma to File PPP001 With the European Medicines Agency

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal medicinal product to the European Medicines Agency. The pre-marketing application of PPP001 as a herbal medicinal product specifically for the European market in no way changes Tetra’s planned schedule to restart its Phase 3 Oncology Drug Development program for advanced cancer pain that was temporarily suspended in February 2019.
Read more

Tetra Bio-Pharma Files Patent Application to Protect PPP001

Jan. 28, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.
Read more